25 completed, 1 withdrawn. 14 Phase 1, 10 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 14 |
| Phase 3 | 10 | Completed 9, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
Follow LY2605541: new trials by email Literature Review of LY2605541 trials Research Report on LY2605541
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY3192767 in Healthy Participants LY3192767, Basal Insulin Peglispro, Insulin Glargine - Healthy | Phase 1 | Completed | Eli Lilly and Company | 57 | 2017-03-06 | 2019-04-05 |
| A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus Insulin Peglispro, Insulin Glargine - Diabetes Mellitus, Type 2 | Phase 3 | Withdrawn | Eli Lilly and Company | 2015-02-01 | 2016-03-28 | |
| A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics Insulin Peglispro, Insulin Glargine, Insulin Lispro - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Eli Lilly and Company | 24 | 2014-07-01 | 2018-11-01 |
| A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements Insulin Peglispro, Insulin Lispro, Insulin Glargine - Diabetes Mellitus, Type 1 | Phase 1 | Completed | Eli Lilly and Company | 28 | 2014-06-01 | 2019-03-01 |
| A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes Insulin Peglispro, Insulin Glargine - Type 2 Diabetes Mellitus | Phase 3 | Completed | Eli Lilly and Company | 68 | 2014-05-01 | 2019-09-18 |
| A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue Insulin Peglispro, Human Insulin - Diabetes Mellitus, Type 1 | Phase 1 | Completed | Eli Lilly and Company | 24 | 2014-04-01 | 2019-03-06 |
| A Study of Insulin Peglispro in Healthy Male Japanese Participants Insulin Peglispro - Healthy Volunteers | Phase 1 | Completed | Eli Lilly and Company | 11 | 2013-12-01 | 2018-10-19 |
| A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics LY2605541, Insulin Glargine - Type 1 Diabetes Mellitus | Phase 1 | Completed | Eli Lilly and Company | 27 | 2013-11-01 | 2019-03-01 |
| A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes Insulin Peglispro, Insulin Glargine - Diabetes Mellitus, Type 1 | Phase 1 | Completed | Eli Lilly and Company | 15 | 2013-10-01 | 2019-03-11 |
| A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment Insulin Peglispro, Insulin Glargine, Oral Antihyperglycemic Medications (OAMs) - Type 2 Diabetes Mellitus | Phase 3 | Completed | Eli Lilly and Company | 388 | 2013-07-01 | 2019-03-15 |
| A Study of LY2605541 in Healthy Participants LY2605541 - Healthy Volunteers | Phase 1 | Completed | Eli Lilly and Company | 18 | 2013-06-01 | 2018-10-19 |
| A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants LY2605541, Insulin Lispro - Healthy Volunteers | Phase 1 | Completed | Eli Lilly and Company | 40 | 2013-06-01 | 2014-10-21 |
| A Study of LY2605541 in Healthy Participants and in the Elderly LY2605541 - Healthy Volunteers | Phase 1 | Completed | Eli Lilly and Company | 52 | 2013-03-01 | 2018-10-16 |
| A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes LY2605541, Human Insulin NPH, Oral Antihyperglycemic Medications (OAM) - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Eli Lilly and Company | 641 | 2013-03-01 | 2018-05-03 |
| A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes LY2605541, Insulin Glargine - Diabetes Mellitus, Type 1 | Phase 1 | Completed | Eli Lilly and Company | 76 | 2013-02-01 | 2019-03-15 |
| A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes LY2605541, Insulin Glargine - Diabetes Mellitus, Type 1 | Phase 1 | Completed | Eli Lilly and Company | 25 | 2013-02-01 | 2019-06-24 |
| A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus LY2605541, Insulin Lispro - Type 1 Diabetes Mellitus | Phase 3 | Completed | Eli Lilly and Company | 212 | 2013-02-01 | 2018-04-20 |
| A Single Dose Study of LY2605541 in Participants With Liver Impairment LY2605541 - Healthy Volunteers, Hepatic Insufficiency | Phase 1 | Completed | Eli Lilly and Company | 35 | 2012-12-01 | 2018-10-19 |
| A Study of LY2605541 Versus Insulin Glargine on Blood Sugar LY2605541, Insulin glargine - Healthy Volunteers, Diabetes Mellitus, Type 1 | Phase 1 | Completed | Eli Lilly and Company | 22 | 2012-07-01 | 2019-03-08 |
| A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus LY2605541, Insulin glargine - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Eli Lilly and Company | 466 | 2012-05-01 | 2018-04-20 |
Showing 20 of 26. Sign in to see all of them.
Diabetes Mellitus, Type 1 (11) · Diabetes Mellitus, Type 2 (10) · Diabetes Mellitus (1) · Hepatic Insufficiency (1)
United States (16) · Germany (11) · Poland (6) · Puerto Rico (6) · Spain (6) · Hungary (5) · Israel (5) · Russia (5) · Australia (4) · Greece (4) · Japan (4) · Mexico (4) · Romania (4) · Austria (3) · Brazil (3)
PMID 36542287, PMID 28417532, PMID 28587667, PMID 29167192, PMID 22787177, PMID 23193209, PMID 24198302, PMID 26278063, PMID 26577417, PMID 42091767
2016 (1)